menu search

Bofa downgrades takeda on suspension narcolepsy drug trials

Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced the suspension of the Phase II trials of its narcolepsy drug candidate TAK-994 due to ...

October 6, 2021, 11:35 am

Bofa downgrades takeda on suspension narcolepsy drug trials

Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced the suspension of the Phase II trials of its narcolepsy drug candidate TAK-994 due to ...

October 6, 2021, 11:35 am

Bofa downgrades takeda on suspension narcolepsy drug trials

Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced the suspension of the Phase II trials of its narcolepsy drug candidate TAK-994 due to ...

October 6, 2021, 11:35 am

Hagens berman, national trial attorneys, alerts amplify energy corp. (ampy) investors to contact firm's attorneys now, firm investigating possible securities law violations

SAN FRANCISCO, Oct. 6, 2021 /PRNewswire/ -- Hagens Berman urges Amplify Energy Corp. (NYSE: AMPY) investors with significant losses to submit your lo...

October 6, 2021, 9:46 am

Hagens berman, national trial attorneys, alerts amplify energy corp. (ampy) investors to contact firm's attorneys now, firm investigating possible securities law violations

SAN FRANCISCO, Oct. 6, 2021 /PRNewswire/ -- Hagens Berman urges Amplify Energy Corp. (NYSE: AMPY) investors with significant losses to submit your lo...

October 6, 2021, 9:46 am

Hagens berman, national trial attorneys, alerts amplify energy corp. (ampy) investors to contact firm's attorneys now, firm investigating possible securities law violations

SAN FRANCISCO, Oct. 6, 2021 /PRNewswire/ -- Hagens Berman urges Amplify Energy Corp. (NYSE: AMPY) investors with significant losses to submit your lo...

October 6, 2021, 9:46 am

Aim immunotech moving forward to develop ampligen as intranasal coronavirus treatment as it publishes phase i safety data

AIM ImmunoTech Inc (NYSE:AIM) reported that a Phase 1 clinical study of Ampligen as an intranasal treatment for coronavirus (COVID-19) had shown "no s...

October 6, 2021, 8:41 am

Aim immunotech moving forward to develop ampligen as intranasal coronavirus treatment as it publishes phase i safety data

AIM ImmunoTech Inc (NYSE:AIM) reported that a Phase 1 clinical study of Ampligen as an intranasal treatment for coronavirus (COVID-19) had shown "no s...

October 6, 2021, 8:41 am

Aim immunotech moving forward to develop ampligen as intranasal coronavirus treatment as it publishes phase i safety data

AIM ImmunoTech Inc (NYSE:AIM) reported that a Phase 1 clinical study of Ampligen as an intranasal treatment for coronavirus (COVID-19) had shown "no s...

October 6, 2021, 8:41 am

Intellia to test second crispr therapeutic in hereditary angioedema patients

The New Zealand Medicines and Medical Devices safety Authority (MEDSAFE) has signed off Intellia Ther...

October 6, 2021, 8:29 am

Intellia to test second crispr therapeutic in hereditary angioedema patients

The New Zealand Medicines and Medical Devices safety Authority (MEDSAFE) has signed off Intellia Ther...

October 6, 2021, 8:29 am

Intellia to test second crispr therapeutic in hereditary angioedema patients

The New Zealand Medicines and Medical Devices safety Authority (MEDSAFE) has signed off Intellia Ther...

October 6, 2021, 8:29 am

Takeda provides update on tak-994 clinical program

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that a ...

October 5, 2021, 7:33 pm

Takeda provides update on tak-994 clinical program

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that a ...

October 5, 2021, 7:33 pm

Takeda provides update on tak-994 clinical program

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that a ...

October 5, 2021, 7:33 pm

Takeda provides update on tak-994 clinical program

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that a ...

October 5, 2021, 7:33 pm

Takeda provides update on tak-994 clinical program

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that a ...

October 5, 2021, 7:33 pm

Mix telematics, ford pro intelligence bond to optimize road safety, efficiency

MiX Telematics Ltd (NYSE: MIXT) collaborated with Ford Motor Co's (NYSE: F) Ford Pro Intelligence to provide MiX North America customers operating...

October 5, 2021, 4:56 pm

Mix telematics, ford pro intelligence bond to optimize road safety, efficiency

MiX Telematics Ltd (NYSE: MIXT) collaborated with Ford Motor Co's (NYSE: F) Ford Pro Intelligence to provide MiX North America customers operating...

October 5, 2021, 4:56 pm

Mix telematics, ford pro intelligence bond to optimize road safety, efficiency

MiX Telematics Ltd (NYSE: MIXT) collaborated with Ford Motor Co's (NYSE: F) Ford Pro Intelligence to provide MiX North America customers operating...

October 5, 2021, 4:56 pm


Search within

Pages Search Results: